117 related articles for article (PubMed ID: 15186837)
21. Discovering benzamide derivatives as glycogen phosphorylase inhibitors and their binding site at the enzyme.
Chen L; Li H; Liu J; Zhang L; Liu H; Jiang H
Bioorg Med Chem; 2007 Nov; 15(21):6763-74. PubMed ID: 17719791
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
[TBL] [Abstract][Full Text] [Related]
23. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase.
Ban HS; Usui T; Nabeyama W; Morita H; Fukuzawa K; Nakamura H
Org Biomol Chem; 2009 Nov; 7(21):4415-27. PubMed ID: 19830290
[TBL] [Abstract][Full Text] [Related]
24. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
Yamamoto N; Mammadova G; Song RX; Fukami Y; Sato K
J Cell Sci; 2006 Nov; 119(Pt 22):4623-33. PubMed ID: 17062641
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, Biological Activities and Docking Studies of Novel 4-(Arylaminomethyl)benzamide Derivatives as Potential Tyrosine Kinase Inhibitors.
Kalinichenko E; Faryna A; Kondrateva V; Vlasova A; Shevchenko V; Melnik A; Avdoshko O; Belko A
Molecules; 2019 Sep; 24(19):. PubMed ID: 31574962
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.
Bridges AJ; Zhou H; Cody DR; Rewcastle GW; McMichael A; Showalter HD; Fry DW; Kraker AJ; Denny WA
J Med Chem; 1996 Jan; 39(1):267-76. PubMed ID: 8568816
[TBL] [Abstract][Full Text] [Related]
27. Hepassocin activates the EGFR/ERK cascade and induces proliferation of L02 cells through the Src-dependent pathway.
Gao M; Zhan YQ; Yu M; Ge CH; Li CY; Zhang JH; Wang XH; Ge ZQ; Yang XM
Cell Signal; 2014 Oct; 26(10):2161-6. PubMed ID: 24768768
[TBL] [Abstract][Full Text] [Related]
28. Efficient chemoenzymatic synthesis of (S)- and (R)-5-(1-aminoethyl)-2-(cyclohexylmethoxy)benzamide: key intermediate for Src-SH2 inhibitor.
Kamal A; Sandbhor M
Bioorg Med Chem Lett; 2002 Jul; 12(13):1735-8. PubMed ID: 12067549
[TBL] [Abstract][Full Text] [Related]
29. 4-Anilinoquinazolines with Lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase: syntheses, chemical and pharmacological properties.
Albuschat R; Löwe W; Weber M; Luger P; Jendrossek V
Eur J Med Chem; 2004 Dec; 39(12):1001-11. PubMed ID: 15571862
[TBL] [Abstract][Full Text] [Related]
30. Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity.
Kaspersen SJ; Han J; Nørsett KG; Rydså L; Kjøbli E; Bugge S; Bjørkøy G; Sundby E; Hoff BH
Eur J Pharm Sci; 2014 Aug; 59():69-82. PubMed ID: 24769040
[TBL] [Abstract][Full Text] [Related]
31. Butein, a specific protein tyrosine kinase inhibitor.
Yang EB; Zhang K; Cheng LY; Mack P
Biochem Biophys Res Commun; 1998 Apr; 245(2):435-8. PubMed ID: 9571170
[TBL] [Abstract][Full Text] [Related]
32. Modulation of hepatic acute phase gene expression by epidermal growth factor and Src protein tyrosine kinases in murine and human hepatic cells.
Wang Y; Ripperger J; Fey GH; Samols D; Kordula T; Wetzler M; Van Etten RA; Baumann H
Hepatology; 1999 Sep; 30(3):682-97. PubMed ID: 10462375
[TBL] [Abstract][Full Text] [Related]
33. Acute ligand-independent Src activation mimics low EGF-induced EGFR surface signalling and redistribution into recycling endosomes.
Medts T; de Diesbach P; Cominelli A; N'Kuli F; Tyteca D; Courtoy PJ
Exp Cell Res; 2010 Nov; 316(19):3239-53. PubMed ID: 20832399
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
[TBL] [Abstract][Full Text] [Related]
35. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
Sall DJ; Arfsten AE; Bastian JA; Denney ML; Harms CS; McCowan JR; Morin JM; Rose JW; Scarborough RM; Smyth MS; Um SL; Utterback BG; Vasileff RT; Wikel JH; Wyss VL; Jakubowski JA
J Med Chem; 1997 Aug; 40(18):2843-57. PubMed ID: 9288166
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
37. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
Migliaccio A; Di Domenico M; Castoria G; Nanayakkara M; Lombardi M; de Falco A; Bilancio A; Varricchio L; Ciociola A; Auricchio F
Cancer Res; 2005 Nov; 65(22):10585-93. PubMed ID: 16288052
[TBL] [Abstract][Full Text] [Related]
38. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
39. Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.
Kanda R; Kawahara A; Watari K; Murakami Y; Sonoda K; Maeda M; Fujita H; Kage M; Uramoto H; Costa C; Kuwano M; Ono M
Cancer Res; 2013 Oct; 73(20):6243-53. PubMed ID: 23872583
[TBL] [Abstract][Full Text] [Related]
40. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor.
Liechti C; Séquin U; Bold G; Furet P; Meyer T; Traxler P
Eur J Med Chem; 2004 Jan; 39(1):11-26. PubMed ID: 14987830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
